

Steve Sisolak  
Governor  
Richard Whitley, MS  
Director



**DEPARTMENT OF  
HEALTH AND HUMAN SERVICES**  
Division of Health Care Financing and Policy  
*Helping people. It's who we are and what we do.*



Suzanne Bierman, JD, MPH  
Administrator

**NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD**

**Date of Posting:** March 3, 2021

**Date of Meeting:** Thursday, April 22, 2021 at 1:00 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board (DUR).

**Remote Meeting Access:** [Microsoft Teams](#)

Or

<http://bit.ly/2Pt2tGI>

Out of deference to Declaration of Emergency Directive 006 from the State of Nevada Executive Department signed by Governor Sisolak on March 22, 2020 & Emergency Directive 003 signed March 20, 2020, a physical location will not be open to the public for attendance at this time.

*Note: If at any time during the meeting an individual who has been named on the agenda or has an item specifically regarding them included on the agenda is unable to participate because of technical or other difficulties, please email Tanya Benitez at [tbenitez@dhcfnv.gov](mailto:tbenitez@dhcfnv.gov) and note at what time the difficulty started so that matters pertaining specifically to their participation may be continued to a future agenda if needed or otherwise addressed.*

**Meeting Audio Information:** Follow the instructions that appear on your screen to join the audio portion of the meeting. Audio will be transmitted over the internet.

**For Audio Only:**

Phone: (952) 222-7450  
Event: 882 990 774#

**PLEASE DO NOT PUT THIS NUMBER ON HOLD (*hang up and rejoin if you must take another call*)**

**AGENDA**

**1. Call to Order and Roll Call**

*Nevada Department of Health and Human Services  
Helping People -- It's Who We Are and What We Do*

## 2. General Public Comment

*(Owing to the lack of a physical location for this meeting, public comment is encouraged to be submitted in advance so that it may be included in meeting materials and given attention. No action may be taken upon a matter raised through public comment unless the matter itself has been specifically included on an agenda as an action item. Please provide your name in any comment for record keeping purposes. You may submit comments in writing via e-mail to [tbenitez@dncfp.nv.gov](mailto:tbenitez@dncfp.nv.gov). There may be opportunity to take public comment via telephone, but phone participants should disconnect their call and re-join if they must take another call. Do not place your phone on hold or you may disrupt the meeting for other participants. Public comment may be limited to three minutes per person. **Note: this guidance regarding public comment applies throughout this agenda where public comment is referenced.**)*

Public comments may be related to topics on the agenda or matters related to other topics per NRS 241.020(3)(3)(II).)

## 3. Administrative

- a. **For Possible Action:** Review and Approve Meeting Minutes from January 28, 2021.
- b. Status Update by DHCFP.

## 4. Clinical Presentations

- a. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for Multiple Sclerosis (MS) Agents.
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
- b. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for Hereditary Angioedema Agents.
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
- c. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria and/or quantity limits for Platelet Inhibitors.
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
- d. **For Possible Action:** Discussion and possible adoption of prior authorization criteria and/or quantity limits for Narcolepsy Agents.

- i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
- e. **For Possible Action:** Discussion and possible adoption of prior authorization criteria and/or quantity limits for Anti-Hepatitis Agents.
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
- f. **For Possible Action:** Discussion and possible adoption of prior authorization criteria and/or quantity limits for Calcitonin Gene-Related Peptide (CGRP) Receptor Inhibitor Medications.
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
- g. **For Possible Action:** Discussion and possible adoption of prior authorization criteria and/or quantity limits for Anticonvulsants.
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.

**5. DUR Board Requested Reports**

- a. **For Possible Action:** Opioid utilization – top prescribers and members.
  - i. Discussion by the Board and review of utilization data.
  - ii. Requests for further evaluation or proposed clinical criteria to be presented at a later date.

**6. Standard DUR Reports**

- a. Review of Prescribing/Program Trends.
  - i. Top 10 Therapeutic Classes for Q3 2020 and Q4 2020 (by Payment and by Claims).
- b. Concurrent Drug Utilization Review (ProDUR).
  - i. Review of Q4 2020.
  - ii. Review of Top Encounters by Problem Type.

- c. Retrospective Drug Utilization Review (RetroDUR).
  - i. Status of previous quarter.
  - ii. Status of current quarter.
  - iii. Review and discussion of responses.

**7. Closing Discussion**

- a. Public comment.

(No action may be taken upon a matter raised under public comment period unless the matter itself has been specifically included on an agenda as an action item. Comments will be limited to three minutes per person. Persons making comment will be asked to begin by stating their name for the record and to spell their last name and provide the secretary with written comments.)

- b. **For Possible Action:** Date and location of the next meeting.
- c. Adjournment.

**PLEASE NOTE:** Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to three minutes.

This notice and agenda have been posted online at <http://dhcfp.nv.gov> and <http://notice.nv.gov>, as well as Carson City, Las Vegas, and Reno central offices for the DHCFP. E-mail notice has been made to such individuals as have requested notice of meetings (to request notifications please contact [tbenitez@dhcfp.nv.gov](mailto:tbenitez@dhcfp.nv.gov), or at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730). At this time, in deference to Emergency Directive 006 dated March 22, 2020 and related directives which have discouraged certain in-person activities, notice has not been posted at other physical locations.

If you require a physical copy of supporting material for the public meeting, please contact [tbenitez@dhcfp.nv.gov](mailto:tbenitez@dhcfp.nv.gov), or at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730. Supporting material will also be posted online as referenced above.

**Note: We are pleased to make reasonable accommodations for members of the public with a disability and wish to participate. If accommodated arrangements are necessary, notify the DHCFP as soon as possible and at least ten days in advance of the meeting, by e-mail at [tbenitez@dhcfp.nv.gov](mailto:tbenitez@dhcfp.nv.gov) in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Tanya Benitez at (775) 684-3730.**

Per Nevada Governor Sisolak's Declaration of Emergency Directive 006; Subsection 3: The requirements contained in NRS 241.020 (4)(a) that public notice agendas be posted at physical locations within the State of Nevada are suspended.

Per Nevada Governor Sisolak's Declaration of Emergency Directive 006; Subsection 4: Public bodies must still comply with requirements in NRS 241.020 (4)(b) and NRS 241.020 (4)(c) that public notice agendas be posted to Nevada's notice website and the public body's website, if it maintains one along with providing a copy to any person who has requested one via U.S. mail or electronic mail.

Per Nevada Governor Sisolak's Declaration of Emergency Directive 006; Subsection 5: The requirement contained in NRS 241.020 (3)(c) that physical locations be available for the public to receive supporting material for public meetings is suspended.

Per Nevada Governor Sisolak's Declaration of Emergency Directive 006; Subsection 6: If a public body holds a meeting and does not provide a physical location where supporting material is available to the public, the public body must provide on its public notice agenda the name and contact information for the person designated by the public body from whom a member of the public may request supporting material electronically and must post supporting material to the public body's website, if it maintains one.